

Index

- abnormal condition, diagnostic
 - method claim (*Grams*) 113–114, 115, 121, 122, 128, 131–132, 190
- abstract ideas, exceptions to
 - patentability 3, 97, 188
 - definition of abstractness 96
 - patent-eligibility doctrine 63, 78, 82, 83, 85, 100, 102, 105, 106, 109
- specific cases
 - Bilski v Kappos* 87–88, 94
 - Laboratory Corporation* 150–151
 - Prometheus Laboratories Inc. v Mayo Collaborative Services* 173–174, 179, 180
 - see also* mental processes
- Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) 31
- alarm limits, updating (*Flook* decision) 55–64, 67, 71–77, 164–165, 194–195
- algorithms, patent-eligibility *see* mathematical algorithms or formulas, patent-eligibility
- American Academy of Ophthalmology 32–33
- American Bar Association 39–40
- American Intellectual Property Association 39
- American Medical Association (AMA) 28
- American Medical Council on Ethical and Judiciary Affairs 32
- American Society of Cataract and Refractive Surgery 28, 30, 32
- Anderson, S.D. 29
- Appropriations Committee 34
- Arrhenius equation 164
- Association of Molecular Pathology v U.S. Patent and Trademark Office (AMT v USPTO)* 131–135, 148, 188
 - District Court 131–132
 - Federal Circuit 132–135
 - machine or transformation test 131, 133, 134
- AZA (azathioprine) drugs 119, 126
- Bilski v Kappos* decision 86–109
 - business purpose inventions 77–78, 81, 82, 84–85
 - Federal Circuit’s jurisprudence following 3–4
 - machine or transformation test, rejection as sole test for patentability of a claimed process 77, 78, 80, 84, 86, 90, 91, 109, 191–192
 - and Patents Act (section 101) 3, 51, 77, 79, 80
- binary-coded data, conversion to pure binary form by general-purpose digital computer (*Benson*) 52–55, 66, 67, 194
- biotechnology industry 33–34, 35, 36, 38, 142
 - violation of patent 42, 43, 48
- Blackmun, Justice 55, 65
- blood clotting, process for combating 20–21
- Board of Patent Appeals (BOPA) 1–2, 6, 57, 111
 - decisions 13, 16–27
- Bostyn, S.J.R. 48
- BRCA1/BRCA2 gene sequences, breast cancer link (*AMP v USPTO*) 131–135, 199–200
- Brennan, Justice 55, 65

- Breyer, Justice 5, 86, 120, 147, 148, 150, 151, 152, 153, 155, 156, 189, 193, 197
- Brinkerhoff* decision (that medical treatment methods not patentable subject matter)
- details and impact of case 16–17
 - dubious legal analysis, based on 6 as early decision of BOPA 16–20
 - overruling of 1–2, 6, 25, 187
 - traditional understanding 14–15
 - whether authority for unpatentability of medical treatment methods 1, 2, 24, 25
- Bryson, Justice 89, 132
- Burger, Chief Justice 63, 65
- business, patentability of inventions
- designed for use in 77–78, 81, 82, 84–85
 - claims merely describing methods of doing business 85, 86, 105–106
- cadavers, medical activity practised on 43
- cataract surgery, patent infringement on surgical technique where wound self-sealing 27, 28
- cell therapy 38
- claim-drafting, eligibility restrictions 141
- Classen Immunotherapies, Inc. v Biogen Idec* 188, 190
- District Court 135–137
 - Federal Circuit
 - first judgment 137
 - judgment on remand 138–145
 - machine or transformation test, applying 5
 - and *Prometheus* decision 142
- clearinghouse, use of 100, 101
- Clinton, Bill/Clinton Administration 31, 38, 39
- cobalamin and folate (B vitamin)
- deficiencies, relationship with homocysteine levels *see* homocysteine levels, relationship with folate and cobalamin (B vitamin) deficiencies (*Laboratory Corporation*)
- Committee on the Judiciary of the House 34
- composition of matter, patented use 40–41, 43–45
- computer-implemented methods 100, 104, 108–109, 175
- Prometheus* decision (Supreme Court) 178–185
- Consent Orders 27
- Constitution of the United States, guarantee to promote progress of science and arts 50
- Cotter, C.C. 29
- coumarin compound, use for combating blood clotting 20–21
- Court of Appeals for the Federal Circuit *see* Federal Circuit (US Court of Appeals for the Federal Circuit)
- Court of Customs and Patents Appeals (CCPA) 110, 147, 172
- mathematical algorithms or formulas, patent-eligibility 57, 66, 71, 73, 74, 112–113
- credit card fraud 89–92, 95, 177
- data-gathering steps
- Federal Court decisions 111, 118, 121, 122, 124, 127–128, 132, 142, 144
 - Supreme Court deliberations 155
- diagnostic treatment methods
- abnormal condition, diagnostic method claim (*Grams*) 113–114, 115, 121, 122, 128, 131–132, 190
 - advanced techniques 81
 - comparison of data with standard values 189
 - context of cases 188–189
 - data-gathering steps *see* data-gathering steps
 - defining 189–191
 - definition of ‘medical activity’ 41
 - deviations from standard, explaining 189
 - diagnosis as an intellectual exercise 197
 - examination phase 189
 - homocysteine levels, relationship with folate and cobalamin deficiencies (*Laboratory Corporation*) 116–117, 120, 148–149

- as natural phenomena 193
- as patentable subject matter 6
- patents for, scope of protection 4
- see also* genetic diagnostic methods; medical treatment methods, patent protection
- Dicumarol 22
- digital computers (general-purpose), programmed conversion of numerical information (*Benson*) 52–55, 66, 67, 194
- discoveries
 - acting on the ‘material world’ 7, 11
 - application to make patentable invention 7–8, 11–12
 - distinguished from inventions 7, 12, 17–18
 - where not patentable 7, 8–10, 11–12
 - whether new discovery of use of old process 8, 9, 15, 20
- diseases, proof of causes 12
- DNA, isolation and sequencing of 131–132
- Dooley, C.M. 35
- Douglas, Justice 52
- Dunner, D.R. 31
- duration of patent 14
- Dyk, Justice 89, 100
- epidermis, and fluid injection methods (*Scherer* decision) 22–24
- ethical considerations 13, 14
- European Patent Office (EPA) 197
 - Enlarged Board of Appeal 189
- Farnan, Justice 138
- Federal Circuit (US Court of Appeals for the Federal Circuit) 1, 187
- early patent-eligibility decisions/initial period 2, 3, 110–115
- and Patents Act (section 101), patent-eligibility question under 3, 4
- post-*Bilski* jurisprudence, on claims falling within Supreme Court’s exceptions 3–4
- recent medical patent jurisprudence 118–145
- specific cases
 - Association of Molecular Pathology v U.S. Patent and Trademark Office* 131–135
 - Classen Immunotherapies, Inc. v Biogen Idec* 135–145
 - Laboratory Corporation 4*, 5, 116–118
 - Prometheus Laboratories Inc. v Mayo Collaborative Services* 118–130, 167, 168, 176–182, 184–185
- Fellner, I.J. 6
- fever, creating while keeping body dry to cure disease 19–20
- fluid injection method (*Scherer* decision) 22–24
- folate and cobalamin (B vitamin) deficiencies, relationship with homocysteine levels (*Laboratory Corporation*) *see* homocysteine levels, relationship with folate and cobalamin (B vitamin) deficiencies (*Laboratory Corporation*)
- formulas, mathematical *see* mathematical algorithms or formulas, patent-eligibility
- fraud detection, credit card transactions 89–92, 95, 177
- Frist, B. 36, 37–38
- gamesmanship 141
- Ganske, G. 29, 33, 34–35, 37
- gastrointestinal disorders, thiopurine drug dosage optimisation (*Prometheus* decision) *see* *Prometheus Laboratories Inc. v Mayo Collaborative Services* decision
- gene therapy 38, 48
- genetic diagnostic methods 1, 199–201
 - BRCA1/BRCA2 gene sequences, breast cancer link (*AMP v USPTO*) 131–135, 199–200
 - Genomic Research and Diagnostic Accessibility Act 46–48
 - screening method claim 199, 200
 - thrombosis 115
- Geniesse, Eugene W. (Examiner-in-Chief) 26

- Genomic Research and Diagnostic
Accessibility Act (GRDA) 46–48
- gonadotropic pituitary hormone,
administration of 20
- Hatch, O.G. 38
- hedging risk (*Bilski*) 82, 83, 97, 103, 139
- homocysteine levels, relationship
with folate and cobalamin (B
vitamin) deficiencies (*Laboratory
Corporation*) 116–117, 120, 190
- ‘correlate’ test 148, 150
- Supreme Court deliberations
148–150, 152, 153, 154, 155, 156
- Hoskins, H.D. 32
- host cells, growth rate (BRCA1/
BRCA2 gene sequences) 131–135,
199–200
- House Bills 2, 28
- House Bill 1127 (HR 1127) 29–33,
36
- House Bill 3610 (HR 3610) 40
- House Bill 3814 (HR 3814) 33–36
- Howell, Justice 170
- hybrid claims, Medical Procedures and
Affordability Act 45–46
- hydrocarbons, catalytic chemical
conversion 56, 57, 62, 71, 103, 165
- ideas 55, 60
- abstract *see* abstract ideas, exception
for
- images, half-toning of 87, 88–89, 95
- infringement 2, 46
- initial determination 6–27
- decisions of BOPA 16–27
- decisions of the courts 7–16
- discoveries and inventions 7–8,
17–18
- instruments, surgical *see Brinkerhoff*
decision (that medical treatment
methods not patentable subject
matter)
- Intellectual Property Owners
Association 39
- inventions
- Brinkerhoff* case *see Brinkerhoff*
decision (that medical treatment
methods not patentable subject
matter)
- designed for business world (*Bilski*)
77–78, 81, 82, 84–85
- distinguished from discoveries 7, 12,
17–18
- ideas 55, 60
- patentable 7–8, 11–12
- patentable versus unpatentable 159
- as processes 79
- whether new 8, 14
- inventiveness 60
- Judiciary Committee (House
Committee on the Judiciary) 35,
36
- Kelman, C.D. 30, 32
- Kennedy, F. 34, 35–36, 78
- Kirk, J.R. 39
- Kirk, M. 31, 37
- knowledge databases, patient
information 173
- Laboratory Corporation* decision 4, 5,
51, 148–157, 188, 190
- Federal Circuit consideration
116–118
- Lafferty, W.B. 29
- laws of nature, exceptions to
patentability 3, 79, 82, 105, 109
- application of, constituting
patentable subject-matter
153–154, 162, 166, 196, 198, 200
- discoveries and inventions 11, 12, 19
- Laboratory Corporation* decision
150–151
- mathematical algorithms or formulas
53, 58, 59, 60, 63, 76
- Prometheus* decision, Supreme Court
165–166, 190, 191, 192
- see also* natural phenomena
- legislative intervention 28–49
- cost/benefit considerations 38
- exclusion, nature 40–46
- Genomic Research and Diagnostic
Accessibility Act (GRDA)
46–48
- history 29–40
- House Bill 1127 (HR 1127) 29–33,
36
- House Bill 3814 (HR 3814) 33–36

- precipitated by potential infringement liability of practitioners 2
- Senate Bill 1334 36–40
- light rays, use for skin conditions 18
- Linn, Justice 100, 178
- living animal tissues, method and apparatus for determining characteristic of 15
- Lourie, Justice 132
- machine or transformation test 85, 188, 191–193
 - applying 5, 125–129
 - failure while still constituting eligible subject matter 177
- Industrial Age/Information Age 81, 85
- machine prong 126, 174–175, 181
- mathematical algorithms or formulas, patent-eligibility 54, 66
- rejection as sole test for determining patentability under section 101 77, 78, 80, 84, 86, 90, 91, 109, 171, 186, 192, 193
- specific cases
 - Association of Molecular Pathology v U.S. Patent and Trademark Office* 131, 133, 134
 - Bilski v Kappos* decision 77, 78, 80, 84, 86, 90, 91, 109, 191–192
 - Prometheus Laboratories Inc. v Mayo Collaborative Services* decision 5, 121, 123, 125–129, 171, 173, 174, 192
- transformation prong 121, 125, 126, 176, 177
- manipulative steps 23–24, 115
- Marshall, Justice 55, 65
- mastitis treatment 13
- mathematical algorithms or formulas, patent-eligibility 52–64
 - abnormal condition, diagnostic method claim (*Grams*) 113–114, 115, 121, 122, 128, 131–132, 190
 - alarm limits, updating (*Flook* decision) 55–64, 67, 71–77, 164–165, 194–195
 - application of algorithm or formula to solve specific problem 61, 196
 - determining step (*Meyer*) 111
 - differentiation between use as invention and as inventive concept 61–62
 - general-purpose computers as specific-purpose once programmed 93
 - ideas 55, 60
 - implementation in specific manner to define structural relationships 114
 - initialising step (*Meyer*) 111
 - invention, defining 68
 - laws of nature 53, 58, 59, 60, 76
 - machine or transformation test 54, 66
 - modifying step (*Meyer*) 111
 - novelty 56, 57, 59, 60, 64, 65, 68–69, 75
 - numerical information, programmed conversion in general-purpose digital computers (*Benson*) 52–55, 66, 67, 194
 - obviousness 57, 59
 - and Patents Act (section 101) 51, 54, 55, 57, 59, 60, 64, 65, 66, 68, 69, 70, 72, 73, 76
 - post-solution activity 56, 58, 76
 - precedents, patent-eligibility 82
 - process claims 53–54
 - rubber, synthetic: process for curing (*Diehr* decision) 64–71, 72, 75, 195–196
 - selection step (*Meyer*) 111
 - specific cases
 - Benson* 52–55, 66, 67, 194
 - Diehr* 64–71, 72, 75
 - Flook* 55–64, 67, 71–77, 194–195
 - testing step (*Meyer*) 111
 - whether known or unknown at time of claimed invention 59
 - see also* patent-eligibility
- Mayer, Justice 107–108
- medical health care entities, exemption from infringement liability 40

- medical methods, *Prometheus* decision, Supreme Court 169–178
- Medical Procedures and Affordability Act (MPAA) 37
- background to 2, 28
- biotechnology patent, practice of
- patent in violation of 41, 42, 48
- composition of matter, patented use 40–41, 43–45
- defendant 42
- definition of ‘body’ 41
- definition of ‘medical activity’ 40–41, 45
- definition of ‘medical practitioner’ 42
- definition of ‘professional affiliation’ 41
- definition of ‘related health care entity’ 42
- as deprivation of property for public use without compensation 28–29
- and Genomic Research and Diagnostic Accessibility Act 48
- human body, organ or cadaver:
- medical activity practised on 43
- hybrid claims 45–46
- impact of 187–188
- infringement 46
- legislative intention 41–46
- medical activity 42–45
- medical practitioner 41
- nature of exclusion 40–46
- patented machine, use 40
- Medical Procedures Innovation and Affordability Act (House Bill 1127) *see under* House Bills
- medical treatment methods, patent protection
- art, method as 14
- definition of ‘medical activity’ 40–41
- exclusion from protection unless procedures necessary
- components of patentable machine/device (HB 1127) 30
- Laboratory Corporation* decision *see Laboratory Corporation* decision
- scope of protection 1, 3, 4, 50–51
- upsurge in decisions on 4–5
- whether or not practised directly on human body 23–24
- see also* diagnostic methods
- Meier, B.J. 29
- mental processes 53, 91, 92, 94, 193, 197
- application as key to patentability 112
- mental activity, definition
- under Genomic Research and Diagnostic Affordability Act 47
- under Medical Procedures and Affordability Act 40–41, 45
- mental step 22, 129–130, 197
- replacing with computer 112, 113
- milk cows, mastitis 13
- Moore, Justice 132, 138, 142, 143, 144, 145, 158
- Moorhead, C. 34, 35
- Morton v New York Eye Infirmary* decision
- details and impact of case 7–12
- treatment method as a ‘discovery’ 11
- whether authority for
- unpatentability of medical treatment methods 1, 2, 24–25, 26
- whether new discovery or use of old process, using increased quantities of a substance 8, 9, 15
- see also* discoveries; inventions
- MPAA *see* Medical Procedures and Affordability Act (MPAA)
- natural phenomena 3, 193–199
- application of, constituting patentable subject-matter 153–154, 162, 166, 196, 198, 200
- diagnostic methods as 193
- Laboratory Corporation* decision 150–151
- versus patentable process 116
- patent-eligibility 63, 66, 78, 79, 80, 87, 88, 96, 105, 107, 109, 153–154
- Prometheus Laboratories Inc. v Mayo Collaborative Services* decision 119, 130

- see also* laws of nature, exceptions to patentability
- nature, laws of *see* laws of nature, exceptions for
- Newman, Justice 105, 138–141, 168
- Noonan, W.N. 30, 32
- Norwood, C.W. 35
- novelty
- discoveries and inventions 10
 - drugs, known 124
 - hybrid claims 45, 46
 - manipulative steps 23–24
 - mathematical algorithms or formulas 56, 57, 59, 60, 64, 65, 68–69, 75
 - Prometheus* decision 168
 - use claims 44–45
- nucleotide sequences, comparing/analysing (*AMP v USPTO*) 131–135, 199
- numerical information, programmed conversion in general-purpose digital computers (*Benson*) 52–55, 66, 67, 194
- obviousness, mathematical algorithms or formulas 57, 59
- O'Malley, Justice 178
- overprotection, dangers of 151
- pain, insensitivity to 7, 8
- Pallin, J. 31
- Pallin v Singer* decision (one physician seeking to enforce a medical treatment method patent against another physician) 2
- Patent Office, US (PTO) 170–171
- patent system (US)
- core principles of law 51
 - violation of fundamental benefits 38–39
- patent-eligibility doctrine 1, 50–109
- alarm limits, updating (*Flook*) 55–64, 67, 71–77, 164–165, 194–195
 - application of phenomena of nature, mental processes and intellectual concepts 53, 54, 79, 116, 151, 153, 158, 159, 160, 185–186, 193–194, 196
- art, machine, manufacture or composition of matter requirement 13–14, 33
- Bilski* case, making sense of 86–109
- business, patentability of inventions designed for use in 77–78, 81, 82, 84–85, 86
- certainty of results requirement 17, 25, 187
- claimed methods, usefulness 56–57
- data-gathering steps 111, 118, 121, 122, 124, 127–128, 142, 144
- discoveries 7–12
- early decisions 1–2
- Federal Circuit, controlling precedents 3
- first principles 52–77
- hydrocarbons, catalytic chemical conversion 56, 57, 62, 71, 103, 165
- ideas 55, 60
- laws of nature *see* laws of nature, exceptions for
- machine or transformation test *see* machine or transformation test
- mathematical algorithms or formulas *see* mathematical algorithms or formulas, patent-eligibility
- methods or modes of treatment of physicians 17
- natural phenomena *see* natural phenomena
- new use/indication for drug/biotechnological process 33–34, 38, 166
- numerical information, programmed conversion in general-purpose digital computers (*Benson*) 52–55, 194
- post-solution activity 56, 58, 76, 136, 142
- practical application of new principle requirement 10, 11–12, 18, 53, 112
- precedents 82–83
- process patentable only if tied to particular machine/apparatus or transforms particular article into different state or thing (*Bilski*) 77, 78, 97

- reconsideration 77–86
- rubber, synthetic: process for curing (*Diehr* decision) 64–71, 72, 75, 195–196
- subject-matter patentability 54, 64, 95, 96, 105, 107, 141, 170, 171, 175, 176, 182, 201
- substances and compositions of matter for treating human body 6
- threshold inquiry, versus substantive conditions of patentability 96
- unintended implications 141
- see also* discoveries; inventions; Patents Act (section 101)
- Patent Act (section 101) 5, 8, 27
- Bilski* decision 3, 51, 77, 79, 80
- Brinkerhoff* decision 14–15
- controlling precedents on patent-eligibility 3, 4
- diagnosis of abnormal condition, whether patentable under (*Grain*) 113–114, 115, 121, 122, 128, 131–132, 190
- machine or transformation test, whether sole test for determining patentability under 77, 78, 80, 84, 86, 90, 91, 109
- mathematical algorithms or formulas, patent-eligibility 51, 54, 55, 57, 59, 60, 64, 65, 66, 68, 69, 70, 72, 73, 76
- Prometheus* decision 5, 120, 122, 124, 125, 160, 162, 164
- scope of protection under 1, 3, 4, 50–51, 124
- physical phenomena *see* natural phenomena
- physicians
 - exemption from infringement liability 40
 - methods or modes of treatment not patentable 17
 - removal of remedies against where patents infringed 29
- pixel-by-pixel comparison, half-toning of images 87, 88–89, 95
- Plager, Justice 101–102, 105, 168
- Portman, R.M. 29
- post-solution activity 136, 142
 - mathematical algorithms or formulas 56, 58, 76
- Powell, Justice 65
- process
 - for clotting of blood, combating 20–21
 - definition 19, 50, 54, 56, 79, 82, 84, 96
 - existing, whether new discovery of use 8, 9, 10, 15, 20
 - invention as 79
 - patentable process versus unpatentable principle 58, 143–144, 195–196
 - previously accepted by courts 26
- process claims 53–54
- Prometheus Laboratories Inc. v Mayo Collaborative Services* decision 111, 188
 - abstract ideas exception 173–174, 179, 180
 - ‘administering’ step 163, 192
 - applying 169–185
 - computer-implemented methods 178–185
 - medical methods 169–178
 - and *Classen* decision 142
 - ‘comparison step’ 189, 190
 - data-gathering steps 118, 121, 122, 124, 127–128
 - ‘determining step’ 163
 - District Court 118–120
 - dosage considerations 119, 122, 125, 126, 127, 129, 133, 191
 - Federal Circuit 118–130, 167, 168, 176–182, 184–185
 - first judgment 120–122
 - judgment on remand 123–130
 - fundamental principle or application of fundamental principle 120–121
 - interpretation of claims 123–125
 - laws of nature exclusion 165–166, 190, 191, 192
 - machine or transformation test 121, 171, 173, 174, 192
 - applying 5, 125–129
 - relevance 123
 - mental step 129–130

- metabolite levels, thiopurine drugs
118, 119, 122, 125, 126, 127,
129, 131, 163, 167, 174, 191
- natural correlations 129
- novelty 168
- and Patents Act (section 101) 5, 120,
122, 124, 125, 160, 162, 164
- precedents 171–172
- pre-emption test 119, 128, 129, 179
- 6-TG/6-MMP metabolite levels 119,
124, 126, 127, 142, 161
- and *SmartGene Inc* decision 5,
169–170, 174
- steps in 129–130, 163, 189–190
- ‘warning’ 118–119, 120, 122, 129,
130, 163
- see also under* data-gathering steps
- Supreme Court Opinion 158–169, 201
- application of decision 169–185
- claims at issue 160–164
- confirmation by controlling
precedents 164–165
- guiding principles 159–160
- laws of nature 165–166
- other arguments 167–169
- rationale for exceptions 158–159
- therapeutic efficacy, optimizing 118,
119, 123, 124
- ‘warning’ step (‘wherein’ clause)
118–119, 120, 122, 129, 130, 163
- property investment tool for tax-
deferred exchanges, patentability
102–103
- Prost, Justice 89, 182–185
- public policy/public health
considerations 2, 156, 187, 201
- Rader, Chief Justice 116–117, 138,
141–142
- random analysis techniques 83
- Rehnquist, Justice 63, 65
- relativity, law of 167
- Rivers, L. 41, 48
- Rogers, H. 35
- rubber, synthetic: process for curing
(*Diehr* decision) 64–71, 72, 75,
195–196
- scarlet fever toxin, use for medical
research 12
- Scherer* decision (that medical
treatment methods not outside
scope of patent protection) 6,
187
- claims 22–24
- impact on patentability of medical
treatment methods 6, 27
- overruling of *Brinkerhoff* decision
2, 6, 25
- Schroeder, P. 34, 36
- scientific and technological work:
application of phenomena of
nature, mental processes and
intellectual concepts 53, 54, 79,
116, 151, 153, 158, 159, 185–186,
193–194, 196
- Senate Bills 2, 28
- Senate Bill 1334 36–40
- see also* Medical Procedures and
Affordability Act (MPAA)
- settlement risk 179
- shrinking of living tissue, method for
18
- Singer, J. 30
- 6-thioguanine (TG)/6-methyl-
mercaptapurine (MMP)
metabolite levels 119, 124, 126,
127, 142, 161
- Skillinton, L. 31
- skin conditions, use of light rays for
18
- Souter, Justice 148, 150
- Stewart, Justice 63, 64, 65
- Stevens, Justice 55, 65, 72, 73, 74, 75,
76–77, 84, 85, 86, 88, 148, 150
- subject-matter patentability 54, 64, 95,
96, 105, 107, 141, 201
- Supreme Court consideration 170,
171, 175, 176, 182
- sulphuric, use in operations 7
- Supreme Court of the United States 1,
147–186
- dismissal of grant of *certiorari* in
Laboratory Corporation 116,
147, 152
- dissenting view 148–157
- exceptions of, claims falling within 3
and Patents Act (section 101),
patent-eligibility question
under 3

- Prometheus* decision 158–169
 - applying 169–185
 - unanimous opinion 157–169
- surgical operations, infringement of
 - patent for improvement of *see* *Morton v New York Eye Infirmary* decision
- susceptibility, methods of testing for 12–13
- systems, testing and analysis (*Meyer*) 110–111, 114–115, 172, 190
- therapeutic agents, as patentable 14
- thiopurine drugs (*Prometheus* decision) 118, 131
 - autoimmune diseases 160–161
 - dosage considerations 119, 122, 125, 126, 127, 129, 133, 191
 - therapeutic efficacy, optimizing 118, 119, 123, 124, 157, 190
 - see also* *Prometheus Laboratories Inc. v Mayo Collaborative Services* decision
- thrombosis, diagnosis of 115, 190
- United States Patent and Trademark Office (USPTO) 1, 48, 50, 187
 - Board of Patent Appeals *see* Board of Patent Appeals (BOPA)
 - House Bills 31, 33
 - University Patents Inc. 148
 - use claims, composition of matter 44–45
- vaccination schedules, relationship with immune-mediated disorders (*Classen Immunotherapies*) 135–145, 190
- violation of patent 41, 44
 - biotechnology industry 42, 43, 48
- White, Justice 55, 65
- Yang, W.W. 29

